Voyager Therapeutics, Inc. (NASDAQ:VYGR) COO Sells $15,712.83 in Stock

Voyager Therapeutics, Inc. (NASDAQ:VYGR) COO Robin Swartz sold 3,087 shares of the stock in a transaction that occurred on Tuesday, January 14th. The shares were sold at an average price of $5.09, for a total transaction of $15,712.83. Following the completion of the transaction, the chief operating officer now owns 109,241 shares in the company, valued at $556,036.69. This represents a 2.75 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Robin Swartz also recently made the following trade(s):

• On Monday, December 23rd, Robin Swartz sold 6,500 shares of Voyager Therapeutics stock. The stock was sold at an average price of $5.65, for a total transaction of $36,725.00.

Voyager Therapeutics Stock Performance

Shares of Voyager Therapeutics stock opened at $5.06 on Friday. Voyager Therapeutics, Inc. has a 52-week low of $4.99 and a 52-week high of $10.66. The firm has a market cap of $276.43 million, a PE ratio of 7.13 and a beta of 0.93. The business’s 50 day simple moving average is $5.95 and its 200 day simple moving average is $6.74.

Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.29. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The business had revenue of $24.63 million during the quarter, compared to the consensus estimate of $12.63 million. During the same quarter last year, the firm earned ($0.59) earnings per share. As a group, equities research analysts predict that Voyager Therapeutics, Inc. will post -0.89 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently commented on VYGR. Wedbush initiated coverage on Voyager Therapeutics in a research note on Friday, November 29th. They set an “outperform” rating and a $11.00 price objective for the company. Leerink Partners assumed coverage on shares of Voyager Therapeutics in a report on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 price target for the company. Cantor Fitzgerald began coverage on shares of Voyager Therapeutics in a research report on Friday, January 10th. They issued an “overweight” rating and a $5.73 price objective for the company. Leerink Partnrs upgraded Voyager Therapeutics to a “strong-buy” rating in a report on Wednesday, October 16th. Finally, Citigroup started coverage on Voyager Therapeutics in a report on Monday, December 2nd. They issued a “buy” rating and a $12.00 price target for the company. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $15.97.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of VYGR. China Universal Asset Management Co. Ltd. raised its stake in shares of Voyager Therapeutics by 64.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock worth $61,000 after purchasing an additional 4,098 shares in the last quarter. Intech Investment Management LLC acquired a new position in Voyager Therapeutics during the third quarter worth $74,000. Victory Capital Management Inc. raised its position in Voyager Therapeutics by 14.5% during the second quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock worth $102,000 after acquiring an additional 1,630 shares in the last quarter. Hsbc Holdings PLC bought a new stake in shares of Voyager Therapeutics in the 2nd quarter valued at about $128,000. Finally, Verition Fund Management LLC bought a new position in Voyager Therapeutics during the third quarter worth about $216,000. 48.03% of the stock is owned by institutional investors and hedge funds.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.